MENU
+Compare
PHCUF
Stock ticker: OTC
AS OF
Aug 7 closing price
Price
$5.87
Change
-$0.13 (-2.17%)
Capitalization
163.49M

PHCUF stock forecast, quote, news & analysis

PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products and specialty pharmaceutical companies... Show more

PHCUF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for PHCUF with price predictions
Sep 05, 2025

Momentum Indicator for PHCUF turns positive, indicating new upward trend

PHCUF saw its Momentum Indicator move above the 0 level on August 21, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator turned positive. In of the 20 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis
Bearish Trend Analysis

The 10-day RSI Indicator for PHCUF moved out of overbought territory on August 07, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 9 similar instances where the indicator moved out of overbought territory. In of the 9 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Aroon Indicator for PHCUF entered a downward trend on September 05, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PHCUF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.271) is normal, around the industry mean (16.681). PHCUF's P/E Ratio (772.718) is considerably higher than the industry average of (74.219). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.902). PHCUF has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.031). P/S Ratio (3.036) is also within normal values, averaging (42.934).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PHCUF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Tilray Brands (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 3.94B. The market cap for tickers in the group ranges from 5.57K to 67.95B. ZTS holds the highest valuation in this group at 67.95B. The lowest valued company is BGPPF at 5.57K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was 0%. For the same Industry, the average monthly price growth was 12%, and the average quarterly price growth was 87%. PCLOF experienced the highest price growth at 90%, while INNPF experienced the biggest fall at -98%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -16%. For the same stocks of the Industry, the average monthly volume growth was 20% and the average quarterly volume growth was 106%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 66
Price Growth Rating: 55
SMR Rating: 82
Profit Risk Rating: 91
Seasonality Score: -18 (-100 ... +100)
View a ticker or compare two or three
PHCUF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
N/A
Address
Hoffsveien 4
Phone
+47 22062210
Employees
106
Web
https://www.photocure.com